Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Microenvironment
Published in: Cancer Microenvironment 1/2015

01-04-2015 | Erratum

Erratum to: Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose Treosulfan

Authors: M. Vogelhuber, S. Feyerabend, A. Stenzl, T. Suedhoff, M. Schulze, J. Huebner, R. Oberneder, W. Wieland, S. Mueller, F. Eichhorn, H. Heinzer, K. Schmidt, M. Baier, A. Ruebel, K. Birkholz, A. Bakhshandeh-Bath, R. Andreesen, W. Herr, A. Reichle

Published in: Cancer Microenvironment | Issue 1/2015

Login to get access

Excerpt

Erratum to: Cancer Microenvironment …
Metadata
Title
Erratum to: Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose Treosulfan
Authors
M. Vogelhuber
S. Feyerabend
A. Stenzl
T. Suedhoff
M. Schulze
J. Huebner
R. Oberneder
W. Wieland
S. Mueller
F. Eichhorn
H. Heinzer
K. Schmidt
M. Baier
A. Ruebel
K. Birkholz
A. Bakhshandeh-Bath
R. Andreesen
W. Herr
A. Reichle
Publication date
01-04-2015
Publisher
Springer Netherlands
Published in
Cancer Microenvironment / Issue 1/2015
Print ISSN: 1875-2292
Electronic ISSN: 1875-2284
DOI
https://doi.org/10.1007/s12307-015-0165-y

Other articles of this Issue 1/2015

Cancer Microenvironment 1/2015 Go to the issue

Original Paper

Tumor-driven Molecular Changes in Human Mesenchymal Stromal Cells

Original Paper

Evaluation of a Hypoxia Regulated Gene Panel in Ovarian Cancer

Original Article

Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose Treosulfan

Original Paper

Stromal Expression of Fibroblast Activation Protein Alpha (FAP) Predicts Platinum Resistance and Shorter Recurrence in patients with Epithelial Ovarian Cancer

Review Paper

Immune Effects of Bevacizumab: Killing Two Birds with One Stone
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits